Souza Cássia Milena de, Bezerra Bárbara Tavares, Mellon Daniel Agreda, de Oliveira Haroldo Cesar
Instituto Carlos Chagas, Fundação Oswaldo Cruz (Fiocruz), Curitiba, PR, Brazil.
Programa de Pós-Graduação em Biologia Parasitária, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil.
Curr Res Microb Sci. 2025 Jan 11;8:100341. doi: 10.1016/j.crmicr.2025.100341. eCollection 2025.
Fungal infections kill more than 3 million people every year. This high number reflects the significant challenges that treating these diseases worldwide presents. The current arsenal of antifungal drugs is limited and often accompanied by high toxicity to patients, elevated treatment costs, increased frequency of resistance rates, and the emergence of naturally resistant species. These treatment challenges highlight the urgency of developing new antifungal therapies, which could positively impact millions of lives each year globally. Our review offers an overview of the antifungal drugs currently available for treatment, presents the status of new antifungal drugs under clinical study, and explores ahead to future candidates that aim to help address this important global health issue.
真菌感染每年导致超过300万人死亡。这一庞大数字反映出在全球范围内治疗这些疾病所面临的重大挑战。目前的抗真菌药物种类有限，且常常对患者具有高毒性、治疗成本高昂、耐药率不断上升以及出现天然耐药菌种。这些治疗挑战凸显了开发新抗真菌疗法的紧迫性，新疗法每年可对全球数百万人的生命产生积极影响。我们的综述概述了目前可用于治疗的抗真菌药物，介绍了正在进行临床研究的新抗真菌药物的情况，并展望了未来有助于解决这一重要全球健康问题的候选药物。
